U.S. markets close in 1 hour 29 minutes
  • S&P 500

    4,162.24
    -23.23 (-0.56%)
     
  • Dow 30

    34,074.09
    -126.58 (-0.37%)
     
  • Nasdaq

    13,905.95
    -146.39 (-1.04%)
     
  • Russell 2000

    2,229.44
    -33.23 (-1.47%)
     
  • Crude Oil

    63.44
    +0.31 (+0.49%)
     
  • Gold

    1,770.20
    -10.00 (-0.56%)
     
  • Silver

    25.83
    -0.27 (-1.05%)
     
  • EUR/USD

    1.2038
    +0.0058 (+0.48%)
     
  • 10-Yr Bond

    1.6050
    +0.0320 (+2.03%)
     
  • GBP/USD

    1.3989
    +0.0149 (+1.08%)
     
  • USD/JPY

    108.1100
    -0.6730 (-0.62%)
     
  • BTC-USD

    55,666.11
    +339.12 (+0.61%)
     
  • CMC Crypto 200

    1,258.86
    -40.09 (-3.09%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Pacira pain drug succeeds in late-stage trial

Feb 27 (Reuters) - Pacira Pharmaceuticals Inc said a late-stage trial testing its drug Exparel for a wider use showed the treatment significantly reduced pain compared to placebo in knee surgery patients.

Exparel is already approved for use in managing post-surgical pain when administered directly at the site of the pain. The latest trial was testing Exparel's efficacy when applied to a major nerve adjacent to the site of the surgery, thereby blocking any sensation until the nerve endings.

A late-stage trial testing the drug, Exparel, showed that patients taking the medicine experienced significant reduction in pain over 72 hours.